Erol K Bayburt

USPTO Granted Patents = 24 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 12)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 7.8

ph-index = 5

Forward Citations = 85(Granted Patents)

Location History:

Gurene, IL (US) (2006 - 2008)
Gurnee, IL (US) (2004 - 2015)

Company Filing History:

15 out of 4,177

Abbott Laboratories Corporation

Years Active: 2004-2015

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9156788 - TRPV3 modulators (2015-10-13),

2. 8772500 - TRPV3 modulators (2014-07-08),

3. 8772499 - TRPV3 modulators (2014-07-08),

4. 8609692 - TRPV1 antagonists (2013-12-17),

5. 8604053 - TRPV1 antagonists (2013-12-10),

6. 8487116 - Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2013-07-16),

7. 8440691 - Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof (2013-05-14),

8. 8350083 - Antagonists of the TRPV1 receptor and uses thereof (2013-01-08),

9. 8338603 - TRPV1 antagonists (2012-12-25),

10. 8247413 - Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2012-08-21),

11. 8232309 - Prodrugs of compounds that inhibit TRPV1 receptor (2012-07-31),

12. 8084616 - TRPV1 antagonists (2011-12-27),

13. 8071762 - Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2011-12-06),

14. 8030504 - Antagonists of the TRPV1 receptor and uses thereof (2011-10-04),

15. 8026256 - Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor (2011-09-27),

Title: Erol K. Bayburt - Innovator in TRPV3 Modulation

Introduction

Erol K. Bayburt, based in Gurnee, IL, is a distinguished inventor with a remarkable portfolio of 24 patents. His innovative work primarily focuses on TRPV3 modulators, contributing significantly to the field of molecular development and therapeutic strategies.

Latest Patents

Among his latest contributions, Erol has developed modulators of TRPV3 with precise chemical formulations. The first patent outlines modulators represented by a specific formula, detailing the components such as G, X, Z, R, and u, as defined in the specifications. This patent presents compositions comprising these compounds and methods aimed at treating various conditions and disorders. Another notable patent similarly describes TRPV3 modulators, expanding the formulations to include variable values for p (1, 2, 3, or 4) while maintaining the importance of the chemical components previously defined.

Career Highlights

Erol has garnered valuable experience working with prominent companies in the pharmaceutical and biotechnology sectors. He has contributed to Abbott Laboratories Corporation and AbbVie Inc., both of which are known for their innovative approaches and research-driven environment.

Collaborations

Throughout his career, Erol has collaborated with esteemed professionals such as Arthur Gomtsyan and Robert G. Schmidt. These partnerships have helped foster advancements in his projects, leading to the successful development of numerous patents.

Conclusion

Erol K. Bayburt stands out as a notable innovator in the field of TRPV3 modulation. His extensive patent portfolio reflects his commitment to advancing medical science and addressing complex health challenges through his inventions. With a solid foundation of collaboration and a track record of impactful work, Erol continues to be a significant contributor to innovations in healthcare.

This text is generated by artificial intelligence and may not be accurate.